WorldCat Identities

Jurczyszyn, Artur

Overview
Works: 9 works in 13 publications in 2 languages and 21 library holdings
Roles: Author
Publication Timeline
.
Most widely held works by Artur Jurczyszyn
Kuchnia i medycyna XXI wieku : żywienie w przebiegu nowotworów by Ewa Ceborska-Scheiterbauer( Book )

4 editions published between 2015 and 2020 in Polish and held by 6 WorldCat member libraries worldwide

Rare Manifestations of Multiple Myeloma by Artur Jurczyszyn( )

2 editions published in 2013 in English and held by 3 WorldCat member libraries worldwide

Rare Manifestations of Multiple Myeloma
Szpiczak mnogi : kompleksowa diagnostyka i terapia( Book )

1 edition published in 2010 in Polish and held by 2 WorldCat member libraries worldwide

Dla hematologów, onkologów i lekarzy innych specjalności
Szpiczak mnogi : praktyczny przewodnik dla pacjentów( Book )

1 edition published in 2016 in Polish and held by 2 WorldCat member libraries worldwide

Amyloidoza : poradnik dla pacjentów( Book )

1 edition published in 2018 in Polish and held by 2 WorldCat member libraries worldwide

Jak aktywnie żyć z nowotworem : poradnik( Book )

1 edition published in 2021 in Polish and held by 2 WorldCat member libraries worldwide

Szpiczak mnogi : wybrane zagadnienia( Book )

1 edition published in 2011 in Polish and held by 2 WorldCat member libraries worldwide

Cytokiny w patogenezie szpiczaka mnogiego : praca doktorska by Artur Jurczyszyn( Book )

1 edition published in 2003 in Polish and held by 1 WorldCat member library worldwide

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and bridges monoclonal gammopathy of undetermined significance to multiple myeloma (MM), based on higher levels of circulating monoclonal immunoglobulin and bone marrow plasmocytosis without end-organ damage. Until a Spanish study reported fewer MM-related events and better overall survival among patients with high-risk SMM treated with lenalidomide and dexamethasone, prior studies had failed to show improved survival with earlier intervention, although a reduction in skeletal-related events (without any impact on disease progression) has been described with bisphosphonate use. Risk factors have now been defined, and a subset of ultra-high-risk patients have been reclassified by the International Myeloma Working Group as MM, and thus will require optimal MM treatment, based on biomarkers that identify patients with a>80% risk of progression. The number of these redefined patients is small (<"0%), but important to unravel, because their risk of progression to overt MM is substantial (e"0% within 2 years). Patients with a high-risk cytogenetic profile are not yet considered for early treatment, because groups are heterogeneous and risk factors other than cytogenetics are deemed to weight higher. Because patients with ultra-high-risk SMM are now considered as MM and may be treated as such, concerns exist that earlier therapy may increase the risk of selecting resistant clones and induce side effects and costs. Therefore, an even more accurate identification of patients who would benefit from interventions needs to be performed, and clinical judgment and careful discussion of pros and cons of treatment initiation need to be undertaken. For the majority of SMM patients, the standard of care remains observation until development of symptomatic MM occurs, encouraging participation in ongoing and upcoming SMM/early MM clinical trials, as well as consideration of bisphosphonate use in patients with early bone loss. Implications for Practice: Smoldering multiple myeloma is an early stage of myeloma disease and is diagnosed before any symptoms occur. Recent research has redefined the diagnostic criteria for multiple myeloma, offering new insights into testing and classification of this malignancy. Risk factors have now been defined and three biomarkers have been validated that are able to identify patients presenting a high risk of progression toward a symptomatic disease. These biomarkers will help physicians to identify high-risk patients who may benefit from optimal treatment. This article summarizes the views of a European panel of hematologists on the implicated changes in patient care. Abstract : Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and bridges monoclonal gammopathy of undetermined significance to multiple myeloma (MM). A subset of ultra-high-risk SMM patients (<"0%) have been reclassified by the International Myeloma Working Group as MM, with a substantial risk of progression to overt MM (e"0% within 2 years). However, for most SMM patients, the standard of care remains observation until development of symptomatic MM occurs
 
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.00 (from 0.00 for Kuchnia i ... to 0.00 for Kuchnia i ...)

Associated Subjects
Rare Manifestations of Multiple Myeloma
Covers
Alternative Names
Artur Jurczyszyn Polish hematologist

Artur Jurczyszyn polski lekarz, hematolog

Artur Jurczyszyn Pools onderzoeker

Jurczyszyn, A.

Languages
Polish (10)

English (3)